BMY
Bristol-Myers Squibb Company
Cash flow statement
| USDLine, in USD | Last 12 months | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 10.7B | 14.2B | 15.2B | 13.9B | 13.1B | 16.2B | 14.1B | 8.2B | 7.1B | 5.3B | 3.1B | 2.1B | 3.1B | 3.5B | 6.9B | 4.8B | 4.5B | 4.1B | 3.7B | 3.2B |
| 1.37B | 1.31B | 1.25B | 1.21B | 1.12B | 0.97B | 0.75B | 0.84B | 0.95B | 1.06B | 1.22B | 0.82B | 0.53B | 0.54B | 0.55B | 0.37B | 0.42B | 0.73B | 0.94B | 0.84B | |
| Free cash flow | 9.3B | 12.8B | 13.9B | 12.7B | 11.9B | 15.2B | 13.3B | 7.4B | 6.1B | 4.2B | 1.8B | 1.3B | 2.6B | 3.0B | 6.4B | 4.5B | 4.1B | 3.3B | 2.8B | 2.3B |
| Depreciation and amortization | 2.8B | 4.0B | 9.6B | 9.8B | 10.3B | 10.7B | 10.4B | 1.7B | 637M | 789M | 626M | 683M | 829M | 763M | 681M | 628M | 744M | 707M | 816M | 892M |
| Stock-based compensation | 552M | 553M | 507M | 518M | 457M | 583M | 779M | 441M | 221M | 199M | 205M | 235M | 213M | 191M | 154M | 161M | 193M | 183M | 181M | 133M |
| Buybacks | — | 0 | 0 | 5.16B | 8.00B | 6.29B | 1.55B | 7.30B | 0.32B | 2.47B | 0.23B | — | — | 0.43B | 2.40B | 1.22B | 0.58B | — | — | — |
| Dividends paid | 5.12B | 5.05B | 4.86B | 4.74B | 4.63B | 4.40B | 4.08B | 2.68B | 2.61B | 2.58B | 2.55B | 2.48B | 2.40B | 2.31B | 2.29B | 2.25B | 2.20B | 2.48B | 2.46B | 2.21B |
| Dividends per share | 2.52 | 2.49 | 2.42 | 2.31 | 2.19 | 2.01 | 1.84 | 1.68 | 1.61 | 1.57 | 1.53 | 1.49 | 1.45 | 1.41 | 1.37 | 1.33 | 1.29 | 1.25 | 1.24 | 1.15 |
| Free cash flow margin | 18.6% | 26.7% | 28.9% | 28.1% | 25.9% | 32.8% | 31.3% | 28.2% | 27.1% | 20.3% | 9.5% | 7.8% | 16.5% | 18.4% | 36.3% | 21.1% | 20.9% | 17.7% | 15.6% | 14.8% |